Nicholas D Smith

Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity.

Dehua Huang, N. Cosford, Merryl D. Cramer, 2004, Bioorganic & medicinal chemistry letters.

2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.

Dehua Huang, N. Cosford, Merryl D. Cramer, 2004, Bioorganic & medicinal chemistry letters.

Expedited SAR study of an mGluR5 antagonists: generation of a focused library using a solution-phase Suzuki coupling methodology.

N. Cosford, B. Muñoz, Nicholas D Smith, 2004, Bioorganic & medicinal chemistry letters.

3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity.

Mark Washburn, N. Cosford, L. Bristow, 2003, Journal of medicinal chemistry.

3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.

N. Cosford, Merryl D. Cramer, Nicholas D Smith, 2004, Bioorganic & medicinal chemistry letters.